Listen now! 🎧 In this new CME-certified podcast Sara Tolaney, MD (Sara Tolaney) and Melinda Telli, MD (@melindatelli) discuss novel #ADCs in Advanced #BreastCancer .
Listen here ⬇️⬇️
clinicaloptions.com/CE-CME/oncolog…

My sincere thanks SABCS! We have come a long way in TNBC and it felt great to share a summary of all of those advances today. We will keep striving 🙌🏻 #SABCS23

Pre-ASCO treat: #CAPItello291 is now out on NEJM! Meaningful improvement in PFS with capivasertib added to fulvestrant, particularly in Akt-path altered tumors (40%); benefit less clear in non-altered tumors. Tox: diarrhea (72%), rash (38%) & nausea (34%). nejm.org/doi/full/10.10…

Dr. Julia Ransohoff of Stanford Medicine Stanford Health Care is recognized as this year’s Paul Carbone, MD Fellowship Award recipient by ECOG-ACRIN Cancer Research Group co-chair Dr. Mitchell Schnall #CancerResearch #ClinicalTrials #BreastCancer #bcsm

Big news: NATALEE Trial positive at interim analysis. More details to come…

#SABCS22 sara Hurvitz presents DB03 now showing sign OS benefit although medians not reached in either arm. Still no deaths from ILD, overall rate 15.2%. Incredible PFS maintained. Little cumulative tox. Truly an amazing advance for pts. OncoAlert

🔥HOT OFF THE PRESS🔥 – “A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes” by Joshua J. Gruber Melinda Telli, M.D. & Co.

Read it here👇
go.nature.com/3Tuz6iZ
rdcu.be/cXNOl

Thank you Susan G. Komen for your support of this work 🙏🏻

Review of pathologic complete response (pCR) shows that evidence currently available does not support pCR used alone as a reliable surrogate endpoint in neoadjuvant randomized controlled trials for breast cancer. ja.ma/3SJNnIu #BCSM

What kind of oncology patients get immune checkpoint inhibitors inpatient? Oral abstract by Fauzia Riaz, MD, MHS - eye opening. Most are initiating therapy, 27% die while inpt, with mOS of only 47 days. What are we doing besides depriving people of hospice? #ASCOQLTY22

➡️Were you ever told to read 'Simone's Maxims?' as the model for how to navigate academic medicine?

👇🏼Check this out! We've re-imagined the maxims to serve a diverse workforce. Please share!

ascopubs.org/doi/abs/10.120…
Yale Cancer Center Yale Hematology Oncology Fellows YSM Office of Diversity, Equity & Inclusion @YaleMed

Do you work with trainees or collaborators who may be in the dark about the importance of statistical power? A new and fun analogy illuminates what they need to know! Mike Baiocchi doi.org/10.1093/aje/kw…

#ASCO22 open access educational read #bcsm ‘Integrating Immunotherapy Into the Treatment Landscape for Patients With #tnbc Triple-Negative Breast Cancer’ ascopubs.org/doi/full/10.12… with Sibylle Loibl Melinda Telli, M.D. OncoAlert

👉Controversy finally settled.. Ablating all sites of disease in oligometastatic breast cancer #bcsm does NOT improve outcome per randomized NRG-BR002. PFS in pts undergoing ablation of mets + SOC (mostly w SBRT) is 19.5 months vs 23 months in pts who received SOC alone. #ASCO22

Back home from ASCO! Excited and grateful to Conquer Cancer, the ASCO Foundation to have received the Women Who Conquer Cancer YIA in Recognition of an Outstanding Latina Researcher alongside the amazing Ana I. Velázquez Mañana, MD MSc (she/her/ella). Thank you, Manali Patel MD for your mentorship and guidance.

So proud to mentor ⁦Gladys M. Rodriguez, MD, MS⁩ on her YIA ⁦Conquer Cancer, the ASCO Foundation⁩ to develop digital tools to overcome #cancerdisparities among #latinx adults with cancer! Moving beyond description and intervening! ⁦Stanford Cancer Institute⁩ ⁦Stanford Department of Medicine⁩

So, Enhertu has dramatic effects in HER2 3+, and now very impressive findings in HER2 1+ or 2+ (HR same for each group). The question is: is HER2 testing relevant AT ALL for Enhertu activity? The guess is: it won't matter. Looks like an agent with near universal activity.

CNS activity of T-DXd. In 17 pts w/HER2+ BCBM, CNS ORR 73% (11/15) in pts with measurable CNS mets including 7/10 pts with active BCBM. Median # of T-DXd cycles was 12 (2-24) with 42% (7/17) remaining on tx at data cutoff. Sheheryar Kabraji Dr Sarah Sammons Carey Anders Rashmi K. Murthy MD, MBE

Just taking a minute to take it in. After a long time away, feels great to be at #SABCS21 ! Hoping our lives continue to normalize 🙏🏻 #bcsm

Aditya Bardia, MD presents #EMERALD data w/ Elacestrant (1st ph III oral SERD data):

🔹70% visceral Mets, 20% prior chemo

🔺ITT: 1.9 mo vs. 2.8 w/ elacestrant

🔺ESR1m: 1.87 vs. 3.78 months

#bcsm #SABCS21 OncoAlert